Sort by: Date added | Date Published | Most Viewed

Headlines Tagged with Addiction 2,939 headlines found

1 View

Indexation of Tobacco Excise and Customs Duty and Smoking Prevalence Among Australian Adults, 2001–2010: A Serial Cross-sectional Study

inflation-adjusted duty was not associated with changes in smoking prevalence, but it may have prevented upward pressure on prevalence that increasing affordability could have exerted. Frequent increases in duty greater than the growth in both wages and g
Nicotine and Tobacco Research
added Oct 15, 2018 18:49
2 Views

E-cigarette Usage Is Associated With Increased Past-12-Month Quit Attempts and Successful Smoking Cessation in Two US Population–Based Surveys

Compared with 2006, past-12-month quit attempts and smoking cessation increased among adults aged 25–44 in recent years. Current e-cigarette use was associated with increased past-12-month quit attempts and successful smoking cessation among established
Nicotine and Tobacco Research
added Oct 15, 2018 18:49
5 Views

LETTER: WARNER: The Nicotine Continuum and Regulation: Additional Challenges to Converting an Important Concept into Policy: Commentary on Zeller

Mitch Zeller is a tobacco control visionary. He and his colleagues are trying to figure out how to convert that vision into meaningful regulation. The real challenge is to do that in a complicated bureaucracy subject to profound political obstacles to se
Nicotine and Tobacco Research
added Oct 15, 2018 18:44
8 Views

LETTER: Considerations for High-Risk Populations: Response to Zeller’s The Future of Nicotine Regulation: Key Questions and Challenges

Given the complexity and multilayered nature of smoking, and challenges in achieving long-term cessation in these groups, it is important that VLNC cigarettes are part of a multifaceted, comprehensive approach to talking tobacco use among high-risk popul
Nicotine and Tobacco Research
added Oct 15, 2018 18:43
4 Views

Winners and Losers: Communicating the Potential Impacts of Policies: Commentary on Zeller

In sum, aggregates such as net public health impact are convenient for cost-benefit analysis but may not weight outcomes consistent with individual values. Research can identify the interests of key audiences, for example, the key outcomes and affected p
Nicotine and Tobacco Research
added Oct 15, 2018 18:43
5 Views

LETTER: PROCTOR: Acting Now Is Urgent: Commentary on Zeller

Cigarette makers were never able to make combustible cigarettes “cancer free,” but now at least we have the power to make them addiction free. It’s a small and simple step in the direction of genuine harm reduction—which could easily save millions of liv
Nicotine and Tobacco Research
added Oct 15, 2018 18:41
2 Views

LETTER: MYERS: The Debate About Nicotine Regulation: Commentary on Zeller

Gottlieb has set in motion a discussion that has the potential to save millions of lives. The challenge is for his agency to put in place and rigorously enforce the rules that are needed to maximize the positive effect of what he has proposed and allay co
Nicotine and Tobacco Research
added Oct 15, 2018 18:39
3 Views

LETTER: The Debate About Nicotine Addiction and the Role of Medicinal Products: Commentary on Zeller

A potential compromise is to allow nicotine products with high appeal and addiction liability similar to cigarettes to be approved as medicinal products which may limit the appeal among youth and require a different approach to marketing. Adults who are
Nicotine and Tobacco Research
added Oct 15, 2018 18:36
4 Views

LETTER: The United States is not the World: Response to Zeller et al’s Call for Discussion on Nicotine Regulation

So my main suggestion as this enterprise evolves is to put in place mechanisms for overcoming the tendency for US-centric thinking and to place a large health warning on the proposals that these may well not be relevant in other jurisdictions.
Nicotine and Tobacco Research
added Oct 15, 2018 18:33
2 Views

[Nevada] CV SCIENCES LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 in CV Sciences, Inc. to Contact the Firm

lawsuit focuses on whether the Company and its executives violated federal securities laws by failing to disclose that the U.S. Patent and Trademark Office rejected the patent for CVSI-007, the Company’s lead drug candidate for the treatment of smokeless
Business Wire
added Oct 13, 2018 15:22
Sign up for daily headlines All Headlines Featured Headlines U.S. Headlines International Headlines